RXT 110 has agreed to make payments aggregating to $150,000 over the course of the next four months for an interim license.
During the term of the interim license, which may last up to 24 months subject to specified triggers, the RXT 110 will obtain all legal and regulatory approvals required, including obtaining shareholder approval should it be required by the Canadian National Stock Exchange and conduct its legal and technical due diligence with respect to the intellectual property rights subject to the license agreement.
RXT 110 produces anti-microbial filler that performs ‘filling’ and ‘bulking’ functions like calcium carbonate.
The company claims RXT filler, with its anti-microbial ph core in individual particles, enhances product life and eradicates a broad spectrum of known bacteria, fungi, algae and other micro – organisms by suppression of their reproduction.